The efficacy of the anti-herpesvirus drug buciclovir [(R)-9-(3,4-dihydroxybutyl)guanineI was investigated in guinea pigs and mice infected intravaginally with herpes simplex virus type 2. Topical treatment initiated early after infection was efficacious, in contrast to topical treatment delayed 24 h or more. Systemic treatment of infected mice could not prevent the spread of virus to the brain and mortality. Systemically administered buciclovir had an effect in guinea pigs, even after delayed onset of treatment, but this effect required high doses of the drug. Our results suggest that buciclovir has only a limited effect against herpesvirus infections once the virus is present in the nervous systems of infected animals.
(R)-9-(3,4-Dihydroxybutyl)guanine (buciclovir [BCV] ) is a new antiherpetic, acyclic guanosine analog (8). Phosphorylation of BCV by the thymidine kinases induced by herpes simplex virus type 1 (HSV-1) or HSV-2 determines in part the specificity of the drug, as BCV is a poor substrate for cellular kinases (8, 9; K. Stenberg, A. Larsson, and R. Datema, J. Biol. Chem., in press). In herpes simplex virusinfected cells BCV is rapidly phosphorylated to its triphosphate, a specific inhibitor of the viral DNA polymerases (Stenberg et al., in press). Thus, BCV resembles other antiherpetic acyclic guanosine analogs, such as 9-(2-hydroxyethoxymethyl)guanine (acyclovir [ACV]), 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine, and 9-(4-hydroxybutyl)guanine in its mechanism of action (for a review see reference 10) .
In cell cultures BCV and 9-(4-hydroxybutyl)guanine are approximately equally potent in inhibiting the replication of HSV-1 and HSV-2 (7, 8) . However, only BCV shows potent antiviral effects in vivo (2) . These results emphasize the importance of evaluating the antiherpetic guanosine analogs in vivo. In this study we evaluated the efficacy of BCV in experimental genital HSV-2 infections in guinea pigs and mice.
MATERIALS AND METHODS
Materials. The acyclic guanosine analogs BCV and ACV were synthesized at Astra Lakemedel AB (manuscript in preparation). For topical use the drugs were suspended in the water-based cream used by Collins and Oliver (1) for ACV at concentrations of 5, 10, and 20% (wt/wt). The concentrations of BCV in serum were determined as previously described (2) . The cream base without drug was used as placebo.
Viruses. HSV-2 strain 91075 is a clinical isolate and was used in its third cell culture passage (2) . HSV-2 strain MS was obtained from the American Type Culture Collection, Rockville, Md., and was propagated in Vero cells. The effects of BCV on replication of HSV-1 and HSV-2 in several cell lines have been described previously (2) .
Animals, virus inoculation, and chemotherapy. Young, female Dunkin-Hartley guinea pigs (Anticimex, Sollentuna, Sweden) weighing 225 to 250 g were used. Before infection, the vaginal mucosa was slightly injured by using a dry, sterile, cotton-tipped applicator. Subsequently, each animal was infected intravaginally with 7 x 104 PFU of HSV-2 strain MS. This virus concentration gave a genital infection rate of 90 to 100% with less than 5% mortality, at least within the course of the experiment (3 weeks) (13 Table 1 ) occurred between drug-and placebo-treated animals (P < 0.001) and between animals treated with 5% and 10% BCV (P < 0.05), but not between placebo-treated and untreated animals.
Vaginal swabs for recovery of herpes simplex virus were taken on days 1, 2, 3, 4, and 7 p.i. from both infepted guinea pigs and mice, placed in 1 ml of Eagle minimal essential medium containing 10% fetal calf serum, and stored at -70°C until analysis. The geometric mean of the vaginal virus titer for each group of animals was determined after titration of the virus on rabbit cornea cells. Carry-over of residual drug fro,m the genital tract to the virus assay system did not occur (data not shown). Spinal marrow and brains from infected mice were removed on the days indicated below. The tissues were weighed and homogenized, and the virus titers were determined as described above.
Statistical analysis. The Mann-Whitney U test was used to compare the lesion score data (the cumulative scores) and the mean day of death for the control and treated animals.
The final mortality rates of the control and treated animals were compared by using a power analysis (6) . Differences in virus titers were compared by using Student's t test for groups of animals or, when possible, by using statistics on paired observations. RESULTS Genital HSV-2 infections in female guinea pigs. Intravaginal inoculation of guinea pigs with HSV-2 strain MS resulted in lesion development (Fig. 1) the amounts of virus recovered from genital swabs on day 1 or 3 p.i. from treated animals showed a significant correlation (day 1, r = 0.86, P < 0.005; day 3, r = 0.69, P < 0.05).
Topical treatments with 10% BCV started 24, 48, or 72 h p.i. produced small but statistically significant effects (Table 1) . These topical treatments decreased intravaginal titers (P < 0.01), as shown in Table 1 , but these decreases were apparently too late or insufficient or both to prevent lesion formation to the same extent as topical treatments started 1 h p.i.
To determine the efficacy of systemic therapy, guinea pigs were treated subcutaneously twice daily with a suspension of BCV (oral gayage of BCV is not efficacious in guinea pigs). As shown in Table 2 , this treatment, which was started 1 h p.i., reduced the cumulative lesion score by 48% (200 mg/kg per day) or by 69% (300 mg/kg per day) and decreased the progression of the disease, but it had no effect on intravaginal virus titers. at least 10-fold (2). Nevertheless, this treatment did not affect the cumulative mortality or the mean day of death and had no effect on virus replication in vaginas (data not shown). Supplying BCV in the drinking water (1 mg/ml) immediately after intravaginal infection resulted in an average serum level of BCV of 3.1 ± 0.6 ,uM (n = 10), but did not decrease the final, cumulative mortality rate, although the mean day of death increased significantly (Table 4) . Treatment with ACV did decrease the cumulative mortality rate (positive control). Drinking water therapy with 2 mg of BCV per ml resulted in no improvement (Table 4) , and this therapy with animals infected with one-tenth the virus dose gave results similar to those shown in Table 4 and did not b See Materials and Methods. Treatment was started 1 h p.i. c The differences in the cumulative mortality rates between placebo-treated animals and drug-treated animals were significant (P < 0.05; power, 90%). The differences between 5 and 10% BCV or 5 and 20% BCV for strain MS or between 10 and 20% BCV for strain 91075 were not significant. d The differences in the mean day of death between placebo-and nontreated animals were significant for strain MS (P < 0.01) but not for strain 91075. The differences between placebo-treated and drug-treated animals were significant (P < 0.05). No significant differences were observed between the 10 and 20o BCV treatments. BCV applied topically soon after genital HSV-2 infection decreased the severity of genital herpes in guinea pigs and the rate of mortality in mice. This effect was probably due primarily to inhibition of HSV-2 replication (Table 1) and spread in non-nervous system tissues contiguous to the genitourinary tract. In guinea pigs the decrease in lesion formation observed after 4 days ( Fig. 1 ) was associated with a decrease in early intravaginal virus replication caused by BCV. Indeed, in guinea pigs topical application of BCV had only a poor effect when treatment was started 2 to 4 days p.i. (i.e., once the infection had progressed beyond the initial site of replication) (3). Likewise, in mice topically applied antiviral agents have no effect on the final mortality rate when virus is present in nervous system tissues 24 h p.i. (5) .
As the first symptoms of genital herpes in guinea pigs (redness and swelling) do not appear until 3 days p.i., it appears that topical treatment of symptomatic genital herpes with BCV has little effect. This is interesting, because topical treatment of guinea pigs infected intradermally on their backs with HSV-2 strain MS does result in good therapeutic effects if treatment starts when erythema occurs (unpublished data).
We could not show a beneficial effect of intraperitoneal or oral administration of BCV to mice with HSV-2 genital infections, although intraperitoneal or oral treatment with BCV at one-tenth the dose used for genital infections very effectively prevented encephalitis caused by systemic HSV-2 infections in mice (2) . In systemically infected mice, BCV inhibited virus replication in visceral organs and, therefore, the spread of virus to the central nervous system (2) . However, in genitally infected mice HSV-2 spread rapidly to nervous tissues, and because systemically administered BCV did not affect intravaginal titers, poor penetration of nervous tissues by BCV may explain the lack of an effect by BCV in genitally infected mice. Indeed, BCV also has poor efficacy in HSV-2-induced herpes encephalitis in mice (unpublished data).
The large subcutaneous doses of BCV needed in guinea pigs to reduce genital lesion development do not affect initial, intravaginal virus replication, possibly because the drug is not distributed to cervicovaginal secretions. These doses are presumably required to prevent replication and spread of HSV-2 in the nervous system, as the onset of genital lesion formation is preceded by spread of HSV-2 in the nervous system (13) . High serum levels cannot be obtained by oral administration of BCV in guinea pigs because of the low oral bioavailability of BCV (unpublished data). Taken together, these results suggest that the low efficacy of systemically administered BCV in experimental genital herpes could be due to poor penetration of the drug into nervous tissues. In fact, this may be a major difference with systemically administered ACV, which also is not able to reduce intravaginal virus replication, but can prevent genital lesion development at lower doses than BCV (4). Full support of this hypothesis will require extensive pharmacokinetic studies, which are now under way.
